They are not two equivalent contrast options in routine MRI. Mangafodipir (Teslascan), the best-documented manganese-based agent in the sources reviewed, had its EU authorization withdrawn in 2012; a 2024 review reports that no manganese-based MRI contrast agent is commercially available for human use. Gadolinium-based contrast agents (GBCAs) remain in clinical use, with indications and risks that vary by agent. The available evidence does not establish that either metal class is categorically safer.
What is the practical difference?
The central difference is availability: mangafodipir is a historical clinical agent, not an established current alternative to the GBCAs used in practice. The clearest overlap in documented use is liver imaging, but the products and their evidence are not interchangeable.
As an Amazon Associate I earn from qualifying purchases.
| Comparison | Manganese example: mangafodipir (Teslascan) | Gadolinium example: gadoxetate (Eovist) |
|---|---|---|
| Status | The European Medicines Agency (EMA) records EU authorization from 22 May 1997 and withdrawal on 21 June 2012 for commercial reasons. A 2024 review reports no manganese-based MRI contrast agent commercially available for human use. | U.S. labeling remains available for Eovist and other GBCAs; indications depend on the specific product and jurisdiction. |
| Documented liver use | Historically authorized to detect suspected liver metastases or hepatocellular carcinoma; also authorized as an adjunct in investigating focal pancreatic lesions. | The current U.S. Eovist label indicates MRI to detect and characterize focal liver lesions in adults and pediatric patients, including term neonates, with known or suspected focal liver disease. |
| Handling in the body | EMA’s scientific assessment describes manganese release or exchange, with manganese mainly excreted through bile and fodipir metabolites excreted through the kidneys. | Gadolinium can be retained in tissues for months or years. Retention varies by agent and tissue, and is generally greater with linear than macrocyclic agents. |
| Key safety considerations | Historical trial tolerability and preclinical findings do not establish a general safety advantage or make it a current routine alternative. | Labels warn about nephrogenic systemic fibrosis (NSF) in people with impaired elimination and describe gadolinium retention. Risk assessment is agent- and patient-specific. |
The Eovist label is a specific example, not a summary of every GBCA: other agents have different indications and characteristics.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errorsWhat was manganese contrast used for?
Teslascan’s former indication
Teslascan contained mangafodipir trisodium. Its EU authorization covered diagnostic MRI of liver lesions suspected to be metastatic disease or hepatocellular carcinoma, and use as an adjunct in investigating focal pancreatic lesions. The marketing authorization holder requested withdrawal for commercial reasons; the authorization ended on 21 June 2012, according to the EMA.
Historical imaging and safety findings
A 1997 phase III multicentre study of 82 patients found more liver lesions on mangafodipir-enhanced T1-weighted images than on unenhanced sequences. In that study, 17% of patients experienced mild-to-moderate adverse events. This is evidence about the historical agent and study protocol, not a comparison with today’s GBCAs.
A separate U.S. multicentre safety study published in 2000 included 546 adults. It reported adverse events in 23% of participants, most mild to moderate; nausea (7%) and headache (4%) were the most commonly reported. Infusion-associated discomfort was reported by 69%, including heat (49%) and flushing (33%). These figures describe that study population and protocol and should not be read as universal rates or compared directly with rates for another agent.
Rank #2
The EMA’s historical scientific assessment describes dephosphorylation and transmetallation, processes through which manganese ions are released or exchanged. It also identifies the liver and, to a lesser extent, the kidneys as target organs in repeated-dose animal toxicity studies, and records reproductive toxicity findings in animals. Those preclinical findings are not, by themselves, proof of the same effects in people.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallOutdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWhat are the safety concerns with gadolinium?
Kidney disease and NSF
GBCAs can increase the risk of nephrogenic systemic fibrosis, a serious condition, in people whose bodies cannot clear the agent adequately. The Eovist prescribing information describes the greatest risk in chronic severe kidney disease and acute kidney injury. This is not a reason to treat every GBCA or every patient as having the same level of risk.
Rank #3
An ACR-NKF consensus publication says that, depending on the indication, harm from delaying or withholding a group II or III intravenous GBCA in someone with acute kidney injury or an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² may outweigh the NSF risk. The decision depends on the patient’s circumstances, the specific agent, and the diagnostic need.
Retention
Product labeling describes gadolinium retention in several organs for months or years, with the amount varying by agent and tissue. Linear agents generally result in more retention than macrocyclic agents. The Eovist label states that the clinical consequences of gadolinium retention in the brain have not been established in patients with normal renal function.
Rank #4
FDA patient guidance advises minimizing repeat examinations when possible, but not avoiding or deferring a medically necessary GBCA MRI solely because of retention concerns. Ask the radiology and referring teams to weigh the expected diagnostic benefit against the relevant, agent-specific risks.
Is manganese contrast safer than gadolinium?
The evidence here does not support a safety winner. The manganese findings come from studies of a withdrawn agent and historical protocols; they are not contemporary head-to-head trials against currently used GBCAs. Nor does manganese’s status as an endogenous element establish that a manganese-based contrast agent is automatically safer. Safety depends on the specific compound, dose and clinical context, and the evidence reviewed does not show that mangafodipir is safer than a GBCA.
Best Value
What to ask before an MRI with contrast
If you are concerned about an upcoming scan, discuss the decision with your care team rather than stopping or postponing a prescribed MRI on your own. These questions can make the conversation specific:
Quick Recap
- Which exact contrast agent is planned, and what diagnostic question is it intended to answer?
- Do acute kidney injury or severe chronic kidney disease affect the choice or timing of that agent?
- Does a history of contrast reaction or your previous contrast examinations change the plan?
- Would another scan answer the same clinical question reliably, or would it create a diagnostic disadvantage?
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
